ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (GCSF)/FILGRASTIM AS AN ADJUNCT IN CHRONIC HEPATITIS C MANAGEMENT

ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (GCSF)/FILGRASTIM AS AN ADJUNCT IN CHRONIC HEPATITIS C MANAGEMENT

Show other versions (2)

Drug-induced hematotoxicity is the commonest reason for reducing the dose or withdrawing interferon (IFN) therapy in a case o f chronic hepatitis C thus depriving the patient o f a possible cure. Traditionally, severe neutropenia has been considered an absolute contraindication to start antiviral t...

Full description

Bibliographic Details
Main Authors:	Fazal A. Danish, Salman S. Koul, Fazal R. Subhani, Ahmed Ehsan Rabbani, Syeda Yasmin
Format:	Article
Language:	English
Published:	Dow University of Health Sciences 2009-06-01
Series:	Journal of the Dow University of Health Sciences
Subjects:	Chronic Hepatitis C. Neutropenia Hematopoietic growth factors Granulocyte-colony stimulating factor
Online Access:	https://jduhs.com/index.php/jduhs/article/view/1331

Similar Items

ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (GCSF)/FILGRASTIM AS AN ADJUNCT IN CHRONIC HEPATITIS C MANAGEMENT
by: Fazal A. Danish, et al.
Published: (2009-06-01)

Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients
by: Danish Fazal, et al.
Published: (2008-01-01)

ROLE OF GRANULOCYTE COLONY-STIMULATING FACTOR (GCSF)/ FILGRASTIM AS AN ADJUNCT IN CHRONIC HEPATITIS C MANAGEMENT
by: Fazal A Danish
Published: (2009-07-01)

Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia
by: Talapatra Indrajit, et al.
Published: (2006-12-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

White blood cell count and ratıo changes ın newborns after granulocyte colony-stımulatıng factor treatments
by: Melek Buyukeran, et al.
Published: (2021-09-01)

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony‐stimulating factor as support to chemotherapy for lung cancer
by: Xiang Ji, et al.
Published: (2022-01-01)

The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients
by: Ayse Bozkurt Turhan, et al.
Published: (2018-12-01)

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience
by: Emel Isiktas Sayilar, et al.
Published: (2020-01-01)

A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors
by: Tetsuya Sasaki, et al.
Published: (2018-01-01)

The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
by: Anton V. Snegovoy, et al.
Published: (2023-12-01)

Efficacy of recombinant human granulocyte colony stimulating factor in very-low-birth-weight infants with early neutropenia
by: Ru-Jeng Teng, et al.
Published: (2015-02-01)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
by: Yosuke Dotsu, et al.
Published: (2021-09-01)

Clinical manifestations and outcomes of pediatric chronic neutropenia
by: Chuan Wan, et al.
Published: (2012-04-01)

Antiviral therapy in HCV-infected decompensated cirrhotics
by: Danish Fazal, et al.
Published: (2010-01-01)

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
by: Jun Wang, et al.
Published: (2023-09-01)

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
by: Jun Wang, et al.
Published: (2021-03-01)

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
by: Shruti Rastogi, et al.
Published: (2021-10-01)

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
by: Omar M. Halalsheh, et al.
Published: (2022-10-01)

The Evidence for Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Neutrophil Disorders: A Comprehensive Review by the Inborn Errors Working Party Group of the EBMT
by: Shahrzad Bakhtiar, et al.
Published: (2019-10-01)

Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
by: Jae Hee Choi, et al.
Published: (2021-11-01)

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
by: Siw Johannesen, et al.
Published: (2018-11-01)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
by: Sadik Husian, et al.
Published: (2021-09-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
by: Yusuke Kitagawa, et al.
Published: (2020-04-01)

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
by: Farzaneh Ashrafi, et al.
Published: (2018-01-01)

Role of granulocyte colony stimulating factor (G-CSF) in dengue patients with severe thrombocytopenia
by: Kamran Amir Khan, et al.
Published: (2024-01-01)

Role of granulocyte colony stimulating factor (G-CSF) in dengue patients with severe thrombocytopenia
by: Kamran Amir Khan, et al.
Published: (2024-01-01)

Effect of exogenous Granulocyte Colony-Stimulating Factor on ovulation and pregnancy rate in NMRI mice
by: F Golshan, et al.
Published: (2017-05-01)

Granulocyte colony stimulating factor use and adherence to clinical practice guidelines among women with breast cancer living in Puerto Rico: a population-based study
by: Yarixabeth Jiménez Nieves, et al.
Published: (2022-07-01)

Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer
by: Ryota Morinaga, et al.
Published: (2019-08-01)

Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01)

Modulation of the tissue composition of regenerative neuroma by dexamethasone and granulocyte colony-stimulating factor
by: O. M. Grabovyi, et al.
Published: (2023-08-01)

Encapsulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in liposomes prepared by thin film hydration and their transfer to mesenchymal stem cells and cord blood hematopoietic stem cells
by: Sławomir Lewicki, et al.
Published: (2020-04-01)

Recombinant Ganoderma lucidum Immunomodulatory Protein Improves the Treatment for Chemotherapy-Induced Neutropenia
by: Xinhua Lei, et al.
Published: (2020-06-01)

Mobilization of stem cell with granulocyte-colony stimulating factor promotes recovery after traumatic brain injury in rat
by: Mohsen Marzban, et al.
Published: (2010-01-01)

Mobilization of stem cell with granulocyte-colony stimulating factor promotes recovery after traumatic brain injury in rat
by: Mohsen Marzban, et al.
Published: (2010-01-01)

Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor
by: Guro Kristin Melve, et al.
Published: (2016-07-01)

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
by: Ying Jiang, et al.
Published: (2022-11-01)